AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$IMVT

Pande Atul sold $65K of IMVT

Pande Atul sold 1,500 shares of Immunovant, Inc. (IMVT) at $43.27 on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pande Atul
Published Aug 28, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IMVT
Neutral
high confidence
Mentioned
$IMVT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMVTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock price materially.

02

Market read

Limited relevance; primarily of interest to investors monitoring insider activity.

03

What to watch

Potential upcoming dilution or secondary offering not disclosed.

Relevance 2/10Novelty 4/10Timing: 2026-08-28 filing date

Background

Form 4 filings disclose insider transactions; directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$IMVTNeutralHigh confidence
Context

Director Pande Atul sold 1,500 shares for $64,905 on 2026-08-28 via a 10b5-1 plan.

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

Sale amount is modest relative to holdings and market cap; typical for 10b5-1 plans.

Market effects

Sector

None; insider activity does not affect sector trends.

Regional

None; company is US‑listed with limited regional relevance.

Global

None; isolated insider transaction.

Counterpoint

What could challenge this read

If the director anticipates near‑term weakness, the sale could hint at downside.

Key entities

  • Company
    Immunovant, Inc.

    Biotech firm listed on NASDAQ under ticker IMVT.

  • Director
    Pande Atul

    Company director executing a pre‑arranged sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IMVT insider trading history →

Related articles

AUG 6
$IMVTMed

Immunovant, Inc. (IMVT): Results of Operations and Financial Condition

Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory dem

SEC EDGAR 8-K4 min
JUN 2
$IMVTMedAI 9/10

H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data

H.C. Wainwright raised its Immunovant (IMVT) price target to $40 from $35 and kept a Buy rating after positive Phase 2 rheumatoid arthritis data, citing high response rates and suggesting FcRn differs from JAK/TNF therapies. It increased IMVT-1402 success odds to 55% (from 30%) and EV sales multiple to 10x (from 9x). BofA also lifted its target to $43 and peak sales forecast for IMVT-1402 to $6.8B from $5.5B.

finance.yahoo.com4 min
SEP 17
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 26,990 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.79 ($542.78–$564.46, $14.92M total) across 22 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min